ARTICLE | Company News

CHMP backs Pfizer's Xeljanz, Amgen's biosimilar Humira

January 27, 2017 11:37 PM UTC

On Friday, EMA's CHMP backed approval of several therapies including Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) and ABP 501 from Amgen Inc. (NASDAQ:AMGN), a biosimilar of Humira adalimumab.

The committee recommended Xeljanz's approval to treat moderate to severe rheumatoid arthritis in adults who have responded inadequately to or are intolerant to one or more disease modifying anti-rheumatic drugs. FDA approved the oral pan-Janus kinase (JAK) inhibitor in 2012...